Compare Illumina, Inc. (ILMN) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JD.Com Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while JD.Com Inc trades at $31.33 (market cap $45.40B). The key difference: JD.Com Inc is the larger of the two by market cap, and JD.Com Inc pays a 2.99% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | JD | |
|---|---|---|
Market Cap | $28.96B | $45.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $36.17 |
52-Week Low | $91.00 | $25.19 |
Enterprise Value | $30.32B | $31.45B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
JD.com trades at $32.97, up 0.49% with bullish technical signals and strong institutional support. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.74 beating expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analysts maintain a strong buy consensus with $39.50 price target, representing 20% upside potential.
JD offers compelling value with attractive valuation multiples (P/S 0.25, P/E 24.03) and robust cash flow generation. Key risks include regulatory scrutiny of the Ceconomy acquisition and margin pressure from competitive e-commerce markets. The upcoming Q2 2026 earnings on August 13, 2026 will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
